Cerus Corp chief legal officer sells $89,529 in company stock.
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 30,000 shares of company stock for $89,529 on August 17, 2026, as part of a pre-arranged trading plan. This sale occurred while Cerus shares were trading near $2.97, having increased significantly over the past year. Despite the insider sale, the company recently surpassed Q2 2026 financial expectations, though concerns about margin pressure and short-term cash usage persist.
Cerus (NASDAQ: CERS) insider moves to sell more stock after July sale
Chrystal Nikole Jensen, an insider at Cerus (NASDAQ: CERS), has filed a Form 144 notice to sell up to 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 17, 2026. This proposed sale follows a previous sale of 24,329 common shares on July 1, 2026, within the last three months. The filing also details prior restricted stock awards to Jensen in 2021 and 2022.
Cerus Corp chief legal officer sells $89,529 in company stock.
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 30,000 shares of company stock totaling $89,529 on August 17, 2026, as part of a pre-arranged trading plan. The sale occurred while Cerus shares were trading near $2.97, reflecting significant gains over the past year. Despite positive Q2 2026 financial results, including an earnings beat and raised revenue guidance, the company faced concerns regarding margin pressure and cash usage.
Cerus Corp chief legal officer sells $89,529 in company stock. By Investing.com
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 30,000 shares of company stock totaling $89,529 on August 17, 2026, as part of a pre-arranged trading plan. This sale occurred while Cerus shares were trading near $2.97, reflecting significant gains over the past year and week, though InvestingPro analysis suggests the stock might be slightly overvalued. The company recently reported strong Q2 2026 financial results, exceeding revenue and profit forecasts, despite concerns about margin pressure and short-term cash usage.
Cerus (CERS) legal chief sells 30,000 shares in preset plan
Cerus (CERS) Chief Legal Officer Chrystal Jensen sold 30,000 shares of common stock on August 17, 2026, as part of a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $2.9843, with individual prices ranging from $2.92 to $3.04. Following this transaction, Jensen directly holds 936,657 shares of Cerus common stock.
Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS
Assenagon Asset Management S.A. significantly reduced its stake in Cerus Corporation by 74.8% in the second quarter, selling 936,043 shares but still retaining 315,050 shares valued at approximately $920,000. Despite this reduction, institutional investors collectively own 78.37% of Cerus. The biotechnology company reported quarterly revenue of $63.3 million and adjusted EPS of $(0.01), meeting analyst expectations, with analysts projecting a full-year loss of about $0.04 per share.
Baker Bros. cuts Cerus Corporation (CERS) position to 3.2% ownership stake
Baker Bros. Advisors LP and related reporting persons have filed an Amendment No. 13 indicating a reduction in their beneficial ownership of Cerus Corporation (CERS) common stock to 3.2%. This ownership comprises 6,395,431 shares held by Baker Brothers Life Sciences, L.P. and 667, L.P., with Julian C. Baker and Felix J. Baker each individually owning an additional 19,864 shares, totaling 6,415,295 shares for each principal. The updated ownership percentage is based on 201,457,000 shares of common stock outstanding as of June 30, 2026.
Cerus Corp (CERS): ARK Investment, Catherine Wood report 8.95% ownership stake
ARK Investment Management LLC and its CEO/CIO Catherine D. Wood have reported a beneficial ownership stake of 8.95% in Cerus Corp (CERS) common stock through an amended Schedule 13G/A filing. As of June 30, 2026, they collectively own 17,932,099 shares. The filing details ARK's sole voting power over 16,642,316 shares and shared voting power over 226,246 shares, while Catherine Wood reports shared voting power over 16,868,562 shares and shared dispositive power over all 17,932,099 shares.
Cerus Corp (CERS) sees Soleus Capital group report 1.2% beneficial stake
Soleus Capital Master Fund, L.P., and its related entities, including Guy Levy, have filed an amended Schedule 13G indicating beneficial ownership of 2,500,000 shares of Cerus Corporation (CERS) common stock, which represents 1.2% of the outstanding shares. This filing confirms that the group now holds 5% or less of Cerus common stock and exercises shared voting and dispositive power over all reported shares. The shares outstanding figure of 201,524,898 is based on Cerus's Form 10-Q filing from July 16, 2026.
Wasatch Advisors LP Sells 1,897,237 Shares of Cerus Corporation $CERS
Wasatch Advisors LP reduced its stake in Cerus Corporation by 35.9% in the second quarter, selling 1,897,237 shares but still retaining 3.38 million shares valued at approximately $9.9 million. Cerus reported quarterly revenue of $63.3 million and an adjusted loss of $0.01 per share, meeting analyst expectations. The company currently holds a "Hold" consensus rating from analysts with an average price target of $4.00, while insiders have sold shares primarily to cover tax obligations.
Cerus Corp (CERS) Stock News Today
This page provides the latest news and information for Cerus Corp (CERS) stock on TradingKey, a financial information platform. As of August 7th, Cerus Corp's stock closed at $2.350, up 1.29%. The platform also offers an overview, news and analysis, financial data, stock score, technical forecast, ownership details, dividends, and profile information for CERS.
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 17th in its industry, with an average analyst price target of $5.00, suggesting a 113.09% upside. Based on 3 analysts, the stock is rated as a "Buy." The company's expected revenue for the next quarter is $61.60 million, and its EPS for the previous and next quarters is estimated at -$0.01.
Cerus Corp 2Q 2026: Revenue $57.4M, EPS $(0.01) — 10-Q Summary
Cerus Corp (CERS) reported its second-quarter 2026 results, showing revenue of $57.4 million, an increase from $52.4 million in the prior year. The company also narrowed its net loss to $(2.94) million from $(5.71) million, and its diluted loss per share improved to $(0.01) from $(0.03) year-over-year. Key highlights included a 10% rise in product revenue driven by increased disposable platelet/plasma kit and IFC sales in the U.S., progress in Phase 3 trials for the red blood cell system, and expanding global adoption of its products.
CERS Slides After Sharp Repricing Raises Trading Focus
Cerus Corporation (CERS) stock has dropped significantly by 23.88% due to adverse regulatory news and increased bearish sentiment. The company, which operates in blood safety, shows solid revenue growth but remains unprofitable, making it a high-risk, high-reward stock for traders. Analysts note its adequate liquidity but elevated leverage, suggesting a challenging path to sustainable profitability, with traders focusing on whether current price levels will form a base or lead to further decline.
Cerus (NASDAQ:CERS) Announces Earnings Results, Meets Expectations
Cerus (NASDAQ:CERS) announced its earnings results, meeting analyst expectations with a quarterly loss of $0.01 per share and revenue of $63.3 million, slightly above the $62.9 million forecast. The company reported a 10% increase in product revenue to $57.4 million, driven by significant growth in INTERCEPT fibrinogen complex revenue, and raised its 2026 product revenue guidance. Despite a decline in gross margin and negative operating cash flow, Cerus refinanced its debt and submitted its INT200 platelet application to the FDA, with potential approval in early 2027.
Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours
Cerus Corporation reported Q2 2026 results that surpassed analyst estimates for both profit and revenue, with an adjusted EPS loss of $0.01 against an expected loss of $0.03, and revenue of $63.3 million compared to a $62.9 million forecast. Despite the beat and raised full-year product revenue guidance, the company's shares dropped 15.21% in after-hours trading, likely due to investor concerns over margin pressure and negative operating cash flow. The blood-safety company highlighted strong product revenue growth, particularly from its U.S. IFC franchise, and continued progress towards GAAP profitability.
Cerus reports Q2 2026 revenue $63.3M; product revenue $57.4M, raises 2026 product guidance
Cerus reported Q2 2026 total revenue of $63.3 million and product revenue of $57.4 million, marking a 10% year-over-year increase. The company raised its full-year product revenue guidance to $229–$231 million and highlighted accelerating demand for INTERCEPT Fibrinogen Complex in the U.S. Cerus also submitted a PMA for its INT200 illuminator and completed a debt refinancing.
Cerus Corp (CERS) beats Q2 2026 revenue by 7.5% on INTERCEPT surge
Cerus Corp (CERS) exceeded its Q2 2026 revenue expectations by 7.5%, reporting $63 million against an estimated $59 million, driven by the strong performance of its INTERCEPT blood safety franchise. The company also announced a positive outlook for fibrinogen product sales, projecting 40% to 50% growth through year-end. This revenue beat continues an upward trend in quarterly sales for Cerus, while its EPS came in line with estimates at -$0.01.
CERS|Cerus Corp|Price:3.045|Chg%:-0.025
This article provides a comprehensive stock analysis of Cerus Corp (CERS) from TradingKey, highlighting its "relatively healthy" fundamentals and high growth potential. The company's valuation is deemed "fairly valued," ranking it 45 out of 199 in its industry, with high institutional ownership and a "Buy" rating from multiple analysts, who suggest a target price of 4.50. The article details Cerus Corp's business as a biomedical products company focused on blood safety, utilizing its INTERCEPT Blood System, and breaks down Cerus's score across various financial and market dimensions.
Cerus Corp (CERS) Cash Flow
This article provides a detailed cash flow statement for Cerus Corp (CERS), offering both quarterly and annual data for operating, investing, and financing activities over several fiscal years. It breaks down key components such as net income, changes in working capital, capital expenditures, and debt/equity transactions. Additionally, it includes FAQs explaining various cash flow metrics and their relevance for investors.
Cerus Corp (CERS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Cerus Corp (CERS), detailing its income sources by business segment and geographical region. As of the stated update, Product sales account for 88.17% of revenue, with Government Contracts making up 11.83%. Geographically, the United States contributes the majority at 65.18%, followed by Other Countries and France.
Cerus Corp (CERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Cerus Corp (CERS). It shows that the company has not distributed any dividends over the past five years. The page displays current stock metrics, including share price and market capitalization, but no historical payout data is available.
Cerus Corp (CERS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cerus Corp (CERS), listing its major shareholders and their respective holdings, alongside an overview of institutional holdings and their changes over recent quarters. Key individual institutional holders include ARK Investment Management LLC, BlackRock Institutional Trust Company, N.A., and Baker Bros. Advisors LP. The article also categorizes shareholders by type and notes related ETF holdings.
TradingKey
This article provides a detailed quarterly and annual income statement for Cerus Corp (CERS) from FY2012Q1 to FY2026Q1, highlighting key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret Cerus Corp's financial data on TradingKey, emphasizing the importance of analyzing various metrics to understand the company's performance, growth, and profitability.
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cerus Corp (CERS), highlighting its current earnings forecast score of 8.67, ranking 18th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $5.00 for CERS, with most recommending a "Buy." The report also includes expected revenue and EPS for upcoming quarters.
CERS|Cerus Corp|Price:2.879|Chg%:-0.141
Cerus Corporation (CERS) is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety by reducing blood-borne pathogens in donated blood components. The company's INTERCEPT system is used for platelets, plasma, red blood cells, and to produce INTERCEPT Fibrinogen Complex (IFC) and pathogen-reduced plasma. As of Q1 2026, the product business generates the highest revenue for Cerus Corp, accounting for 88.17% of total revenue, and 277 institutions hold shares valued at approximately $147.40 million.
CERS|Cerus Corp|Price:2.879|Chg%:-0.141
Cerus Corp (CERS) shows healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Healthcare Equipment & Supplies industry. Analysts have rated it a "Buy" with a target price of $4.50, suggesting a 44.23% upside. The company specializes in the INTERCEPT Blood System to enhance blood safety and has seen significant institutional buying and revenue growth.
Cerus Corp (CERS) Valuation: PE, PB & Fair Value Analysis
Cerus Corp (CERS) has a current valuation score of 7.27, placing it 159th out of 200 in the Healthcare Equipment & Supplies industry. Its P/E ratio stands at -58.35, which is notably below its recent high and above its recent low. However, data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Cerus (CERS) to Announce Quarterly Earnings on Thursday
Cerus (CERS) is scheduled to announce its Q2 2026 earnings after the market closes on Thursday, July 30th. Analysts anticipate a loss of $0.0133 per share on revenues of $62.90 million. The company's prior quarter surpassed expectations, and its stock was down 3.2% on Thursday, holding a "Hold" consensus rating with a $4.00 price target.
Press Release: Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
Cerus Corporation announced it will release its second quarter 2026 financial results on Thursday, July 30, 2026. This will be followed by a conference call and live webcast in which company management will discuss the results and provide a business update. A replay of the webcast will be available following the event.
Cerus Corporation (NASDAQ:CERS) Short Interest Down 35.3% in June
Short interest in Cerus Corporation (NASDAQ:CERS) significantly decreased by 35.3% in June, falling to 12.74 million shares, although 6.7% of the float remains sold short. Analysts hold a mixed view, with a consensus "Hold" rating and a $4.00 price target, despite recent upgrades. The company exceeded Q1 expectations, reporting a smaller loss and higher revenue than anticipated, while insider selling and consistent institutional ownership were noted.
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
Cerus Corporation announced it will release its second quarter 2026 financial results on Thursday, July 30, 2026, after the stock market closes. The company will also host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview. Interested parties can access the live webcast and presentation slides through the Investor Relations page of the Cerus website.
Cerus Corp (CERS) CEO trades 16666 shares under 10b5-1 plan
Cerus Corp CEO Vivek K. Jayaraman sold 16,666 shares of common stock on July 16, 2026, at a price of $3.16 per share, under a pre-arranged 10b5-1 trading plan. Following this transaction, Jayaraman directly holds 2,232,211 shares of the company's common stock. This insider trading activity was reported in a Form 4 filing, indicating a neutral impact on the company.
Cerus Corporation to release Q2 2026 results on July 30
Cerus Corporation is scheduled to announce its Q2 2026 financial results on July 30, 2026, after the stock market closes. This will be followed by a conference call and webcast at 4:30 P.M. ET to discuss the financial performance, business overview, and future outlook. A replay of the call will be accessible on the company's website until August 20, 2026.
Cerus to Discuss Results and Outlook in July 30 Webcast
Cerus Corporation announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET to discuss these results and provide a business overview and outlook. Interested parties can access the live webcast and presentation slides via the Investor Relations page of the Cerus website.
CERS shareholder (NASDAQ: CERS) details planned stock sales in 2026
Vivek K. Jayaraman, a CERS shareholder, has filed a Form 144 to announce the planned sale of up to 16,666 shares of CERS common stock on July 16, 2026, with an estimated market value of $52,664.56. These shares are restricted stock acquired on March 12, 2021. The filing also discloses prior sales by Jayaraman, including 42,359 shares sold on July 1, 2026, and two blocks of 16,667 shares sold in May 2026.
Cerus Corporation (CERS) defines pay and term for William Greenman as Executive Chairman
Cerus Corporation has updated the employment terms for William Greenman following his transition to Executive Chairman, effective July 1, 2026. He will serve until May 31, 2027, with a reduced time commitment, and will receive an annual base salary of $500,000, plus an 80% target annual cash bonus for 2026 only. The company will also cover COBRA health insurance premiums if his role change qualifies.
Cerus Corp faces a complex landscape as blood safety technology evolves
Cerus Corp operates in the demanding healthcare environment of blood safety systems, focusing on pathogen reduction technology. The company's success relies on the adoption of its systems by blood centers and hospitals, which face regulatory scrutiny, budget constraints, and evolving safety standards. Cerus Corp's strategy involves demonstrating both the clinical effectiveness and economic value of its pathogen reduction systems to ensure long-term integration into transfusion practices.
Cerus Corp updates focus on blood safety. Business model supports long-term growth
Cerus Corp (CERS) focuses on developing medical technologies to enhance blood transfusion safety, particularly through its pathogen reduction systems for platelets and plasma. The company, listed on Nasdaq, aims to reduce the risk of infection from transfused blood components for hospitals and blood centers globally. Its business model, which combines capital equipment sales with recurring consumable revenues, supports long-term growth as more healthcare systems adopt its INTERCEPT Blood System.
Cerus Corp looks to blood safety technology as investors weigh long-term growth
Cerus Corp specializes in pathogen reduction systems for blood components, enhancing transfusion safety globally. The company's business model focuses on expanding its technology and partnerships with healthcare providers and blood centers. Investors are keenly watching the long-term adoption of Cerus technology, its revenue growth, and market expansion as key indicators for future performance.
CERS - Cerus Corp Latest SEC Filings
This article provides comprehensive financial data and market performance metrics for Cerus Corp (CERS), highlighting its latest stock price, financial ratios, sales figures, and insider transaction details. It offers a snapshot of the company's current market position, including volatility, relative volume, and analyst recommendations. The data indicates various performance metrics over different periods, offering insights into its stock trend and financial health.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), sold 24,329 shares of common stock totaling $71,597 on June 30, 2026. These sales were not discretionary but rather to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. Following these transactions, Jensen directly holds 966,657 shares of CERUS CORP.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer of Cerus Corp, sold 24,329 shares of common stock for $71,597 on June 30, 2026. These sales were primarily to cover tax withholding obligations related to restricted stock unit vesting, rather than a discretionary sale. The company recently reported better-than-expected first-quarter 2026 earnings and secured a new debt facility to reduce interest expenses.
Cerus COO Vivek Jayaraman disposes of $124,658 in stock for taxes
Cerus COO Vivek Jayaraman sold $124,658 worth of company stock to cover tax withholding obligations associated with the vesting of restricted stock units. This transaction, occurring on June 30, 2026, involved the sale of 42,359 shares at an average price of $2.9429. Additionally, Jayaraman received a grant of 554,529 Restricted Stock Units and 369,686 performance rights, with vesting schedules tied to continued service and company stock performance, respectively.
Cerus CFO Kevin Green sells $99,105 in CERS shares
Cerus CFO Kevin Green sold 33,676 shares of CERS stock for $99,105 on June 30, 2026, under a pre-arranged trading plan to cover tax obligations from restricted stock unit vesting, not as a discretionary sale. Following these transactions, Green directly holds 1,062,188 shares. The company, with a $627 million valuation, is currently unprofitable and its stock is trading near a 52-week high after a 103% return in the past year.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Chrystal Jensen, Chief Legal Officer at Cerus Corp (NASDAQ: CERS), sold 24,329 shares of common stock for $71,597 on June 30, 2026. These sales were not discretionary but made to cover tax withholding obligations and brokerage fees related to restricted stock unit vesting. The company's stock is currently trading near its 52-week high, with recent first-quarter earnings surpassing expectations and a new debt facility secured for up to $110 million.
Cerus (CERS) CFO logs tax-related share sale and new stock grant
Cerus Corp's CFO, Kevin Dennis Green, reported a non-discretionary sale of 33,676 shares at a weighted average price of $2.94 to cover tax withholding and brokerage fees related to restricted stock unit vesting. On the same date, he also received a grant of 63,600 shares at no cost. Following these transactions, Green directly holds 1,095,864 shares of Cerus common stock.
Cerus (CERS) COO granted RSUs, performance rights and sells shares
Cerus Corp's COO, Vivek K. Jayaraman, received significant equity grants including 554,529 shares of common stock and 369,686 performance rights, with vesting contingent on continued service and the company's stock performance. Concurrently, he sold 42,359 shares worth approximately $125,000 under a pre-set Rule 10b5-1 plan to cover tax withholding and fees, not as a discretionary sale. Following these transactions, Jayaraman holds over 2.2 million common shares and all his performance rights.
Cerus (NASDAQ: CERS) CLO reports Rule 10b5-1 tax sale and 55,000-share grant
Cerus Corp's Chief Legal Officer, Chrystal Jensen, reported two common stock transactions on June 30, 2026. Jensen sold 24,329 shares at a weighted average price of $2.9429 to cover tax withholding obligations and brokerage fees related to vesting restricted stock units under a Rule 10b5-1 plan. On the same day, she also received a grant of 55,000 shares at no cost, increasing her direct holdings to 990,986 shares.
Cerus Corp chief legal officer Chrystal Jensen sells $71,597 in stock
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 24,329 shares of common stock for $71,597 to cover tax obligations related to restricted stock unit vesting. This transaction is not considered a discretionary sale, and Jensen still holds 966,657 shares. The sale occurred while CERS stock is near its 52-week high, and the company recently surpassed Q1 2026 earnings expectations and secured a new debt facility to reduce interest expenses.
